Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on January 9, 2023. The filing serves as a Regulation FD disclosure to announce the posting of an investor presentation on the company's website.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report acts as a notice of an external presentation rather than a financial statement containing quantitative data.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The document solely references the availability of an investor presentation (Exhibit 99.1) for further details.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in the attached investor presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities thereof. Consequently, no specific guidance, outlook, risks, or contingencies are articulated in the body of this 8-K.
Key Facts for Investor Verification
- Verify the content of the Investor Presentation dated January 9, 2023 (Exhibit 99.1) for actual financial guidance and strategic updates.
- Note that the presentation materials are not incorporated by reference into this filing and do not carry the same legal liability as filed financial statements.
- Confirm the trading symbols for the company's registered securities: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).